Results 41 to 50 of about 15,173,912 (274)

Factor XI inhibitors: a new class of anticoagulants [PDF]

Blood Advances
Jean M. Connors
doaj   +2 more sources

Crosstalk between the complement pathway and the contact activation system of coagulation: activated factor XI neutralizes complement factor H.

Journal of Immunology, 2021
Key Points FXIa cleaves CFH at the R341/R342 bonds at the end of the CCP 6 domain of CFH. FXIa reduces CFH cofactor and decay‐accelerating activity and binding to ECs. CFH binds FXI and inhibits FXI activation by either thrombin or FXIIa.
C. Puy, J. Pang, Stéphanie E. Reitsma, C. Lorentz, E. Tucker, D. Gailani, A. Gruber, F. Lupu, O. McCarty   +8 more
semanticscholar   +1 more source

Factor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in Mice. [PDF]

PLoS ONE, 2016
Sepsis, a systemic inflammatory response to infection, is often accompanied by abnormalities of blood coagulation. Prior work with a mouse model of sepsis induced by cecal ligation and puncture (CLP) suggested that the protease factor XIa contributed to ...
Charles E Bane, Ivan Ivanov, Anton Matafonov, Kelli L Boyd, Qiufang Cheng, Edward R Sherwood, Erik I Tucker, Stephen T Smiley, Owen J T McCarty, Andras Gruber, David Gailani   +10 more
doaj   +1 more source

Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI

Proceedings of the National Academy of Sciences of the United States of America, 2021
Significance Prekallikrein (PK) is a zymogen that is converted to kallikrein (PKa) by factor (F)XIIa. PK and FXII reciprocally activate each other; the resulting FXIIa initiates activation of the coagulation system via the cleavage of FXI to FXIa, which ...
Katherine J. Kearney, Juliet M. Butler, O. M. Posada, Clare L Wilson, S. Heal, Majid Ali, Lewis J Hardy, Josefin Ahnström, D. Gailani, R. Foster, E. Hethershaw, C. Longstaff, H. Philippou   +12 more
semanticscholar   +1 more source

Two factor XI mutations in a Chinese family with factor XI deficiency [PDF]

American Journal of Hematology, 2003
AbstractWe describe a Chinese family with factor XI deficiency, the first reported to date. The proband had factor XI activity of 1% and was heterozygous for two nonsense mutations, an exon‐8 C713→T mutation resulting in Gln263→Term, and an exon‐10 C979→A mutation resulting in Tyr351→Term.
Au, WY, Cheung, JW, Lam, CCK, Kwong, YL
openaire   +4 more sources

Acquired Antibody to Factor XI in a Patient with Congenital Factor XI Deficiency [PDF]

Journal of Clinical Investigation, 1982
The results of studies in a patient with congenital deficiency of Factor XI who developed an inhibitor are presented. The patient presented with a severe, apparently spontaneous bleed into the thigh, which progressed despite infusion of fresh frozen plasma, but which responded promptly to activated prothrombin complex.
D M, Stern, H L, Nossel, J, Owen
openaire   +2 more sources

Impact of Deficiency of Intrinsic Coagulation Factors XI and XII on Ex Vivo Thrombus Formation and Clot Lysis

TH Open, 2019
The contributions of coagulation factor XI (FXI) and FXII to human clot formation is not fully known. Patients with deficiency in FXI have a variable mild bleeding risk, whereas FXII deficiency is not associated with bleeding.
José W. P. Govers-Riemslag, Joke Konings, Judith M. E. M. Cosemans, Johanna P. van Geffen, Bas de Laat, Johan W. M. Heemskerk, Yesim Dargaud, Hugo ten Cate   +7 more
doaj   +1 more source

Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds [PDF]

Blood, 1985
The relationship of clinical bleeding tendency and factor XI antigen (XI:Ag) in factor XI deficiency was studied in 78 members of 25 factor XI-deficient kindreds. Factor XI:Ag was measured in a competitive radioimmunoassay, using monospecific, heterologous anti-factor XI antibody.
M V, Ragni, D, Sinha, F, Seaman, J H, Lewis, J A, Spero, P N, Walsh   +5 more
openaire   +3 more sources

Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target.

Kidney International, 2021
Chronic kidney disease (CKD) is present in almost 10% of the world population and is associated with excess mortality and morbidity. Reduced glomerular filtration rate and the presence and extent of proteinuria, key domains of CKD, have both been shown ...
J. Eikelboom, J. Floege, R. Thadhani, J. Weitz, W. Winkelmayer   +4 more
semanticscholar   +1 more source

Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice

Journal of Thrombosis and Haemostasis, 2021
Human coagulation factor (F) XI deficiency, a defect of the contact activation system, protects against venous thrombosis, stroke, and heart attack, whereas FXII, plasma prekallikrein, or kininogen deficiencies are asymptomatic.
A. Ngo, Kelley R. Jordan, P. Mueller, Matthew W. Hagen, Stéphanie E. Reitsma, C. Puy, A. Revenko, C. Lorentz, E. Tucker, Q. Cheng, M. Hinds, S. Fazio, B. Monia, D. Gailani, A. Gruber, H. Tavori, O. McCarty   +16 more
semanticscholar   +1 more source